Condition: Relapsed Refractory Multiple Myeloma (RRMM) · Sponsor: YOUNGIL KOH
The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
This description comes directly from the study's public registry record.
Youngil Koh, MD, PhD · 82-02-2072-7217 · go01@snu.ac.kr
Always discuss trial participation with your own doctor first.
| National University Hospital (NUH) | Singapore, Singapore | Recruiting |
| Singhealth Duke NUS blood cancer center | Singapore, Singapore | Recruiting |
| Chonnam National University Hwasun Hospital | Hwasun, South Korea | Recruiting |
| Asan Medical Center, University of Ulsan College of Medicine | Seoul, South Korea | Recruiting |
| Samsung Medical Center, Sungkyunkwan University School of Medicine | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Not Yet Recruiting |
| Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06645678